Literature DB >> 23558366

Antibiotic susceptibility profiles of neonatal invasive isolates of Escherichia coli from a 2-year nationwide surveillance study in Germany, 2009-2010.

M Heideking1, F Lander, M Hufnagel, Y Pfeifer, E Wicker, G Krause, R Berner.   

Abstract

A nationwide 2-year surveillance study on invasive neonatal Escherichia coli infections in Germany was conducted. A total of 158 isolates were tested for antibiotic susceptibility. The empirical treatment regimen of ampicillin plus gentamicin for neonatal sepsis appears to remain effective, but emerging resistance needs to be closely monitored.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23558366     DOI： 10.1007/s10096-013-1871-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  10 in total

1.  Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues.

Authors:  Barbara J Stoll; Nellie I Hansen; Pablo J Sánchez; Roger G Faix; Brenda B Poindexter; Krisa P Van Meurs; Matthew J Bizzarro; Ronald N Goldberg; Ivan D Frantz; Ellen C Hale; Seetha Shankaran; Kathleen Kennedy; Waldemar A Carlo; Kristi L Watterberg; Edward F Bell; Michele C Walsh; Kurt Schibler; Abbot R Laptook; Andi L Shane; Stephanie J Schrag; Abhik Das; Rosemary D Higgins
Journal:  Pediatrics       Date:  2011-04-25       Impact factor: 7.124

2.  Empirical treatment of neonatal sepsis: are the current guidelines adequate?

Authors:  B Muller-Pebody; A P Johnson; P T Heath; R E Gilbert; K L Henderson; M Sharland
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2010-06-28       Impact factor: 5.747

3.  Neonatal infections in England: the NeonIN surveillance network.

Authors:  Stefania Vergnano; Esse Menson; Nigel Kennea; Nick Embleton; Alison Bedford Russell; Timothy Watts; Michael J Robinson; Andrew Collinson; Paul T Heath
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2010-09-27       Impact factor: 5.747

4.  Neonatal Bacterial Meningitis: 444 Cases in 7 Years.

Authors:  Jean Gaschignard; Corinne Levy; Olivier Romain; Robert Cohen; Edouard Bingen; Yannick Aujard; Pascal Boileau
Journal:  Pediatr Infect Dis J       Date:  2011-03       Impact factor: 2.129

5.  Meningitis caused by Escherichia coli producing TEM-52 extended-spectrum beta-lactamase within an extensive outbreak in a neonatal ward: epidemiological investigation and characterization of the strain.

Authors:  Didier Moissenet; Béatrice Salauze; Olivier Clermont; Edouard Bingen; Guillaume Arlet; Erick Denamur; Audrey Mérens; Delphine Mitanchez; Hoang Vu-Thien
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

6.  Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis.

Authors:  Matthew J Bizzarro; Louise-Marie Dembry; Robert S Baltimore; Patrick G Gallagher
Journal:  Pediatrics       Date:  2008-04       Impact factor: 7.124

7.  Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis.

Authors:  Ana Alarcon; Pilar Peña; Sofia Salas; Marta Sancha; Felix Omeñaca
Journal:  Pediatr Infect Dis J       Date:  2004-04       Impact factor: 2.129

8.  Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany.

Authors:  Sabine Gröbner; Dirk Linke; Wolfgang Schütz; Claudia Fladerer; Johannes Madlung; Ingo B Autenrieth; Wolfgang Witte; Yvonne Pfeifer
Journal:  J Med Microbiol       Date:  2009-06-05       Impact factor: 2.472

9.  Salmonella enterica serovar Typhi with CTX-M beta-lactamase, Germany.

Authors:  Yvonne Pfeifer; Jens Matten; Wolfgang Rabsch
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

10.  Extended spectrum ß-lactamase-producing Escherichia coli in neonatal care unit.

Authors:  Sarah Tschudin-Sutter; Reno Frei; Manuel Battegay; Irene Hoesli; Andreas F Widmer
Journal:  Emerg Infect Dis       Date:  2010-11       Impact factor: 6.883
  10 in total
  7 in total

1.  Escherichia coli early-onset sepsis: trends over two decades.

Authors:  Natalia Mendoza-Palomar; Milena Balasch-Carulla; Sabina González-Di Lauro; Maria Concepció Céspedes; Antònia Andreu; Marie Antoinette Frick; Maria Ángeles Linde; Pere Soler-Palacin
Journal:  Eur J Pediatr       Date:  2017-08-02       Impact factor: 3.183

2.  [Research advances in rational use of antibiotics in neonates].

Authors:  Wen Han; Yun Cao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-10

3.  Distribution of strain type and antimicrobial susceptibility of Escherichia coli isolates causing meningitis in a large urban setting in Brazil.

Authors:  Hillary Berman; Maria Goreth Barberino; Edson Duarte Moreira; Lee Riley; Joice N Reis
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

4.  Optimizing the Use of Antibacterial Agents in the Neonatal Period.

Authors:  Joseph B Cantey
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 5.  Human and avian extraintestinal pathogenic Escherichia coli: infections, zoonotic risks, and antibiotic resistance trends.

Authors:  Melha Mellata
Journal:  Foodborne Pathog Dis       Date:  2013-08-20       Impact factor: 3.171

6.  Population-based study of early-onset neonatal sepsis in Canada.

Authors:  Michael Sgro; Anna Kobylianskii; Mark H Yudin; Dat Tran; Julia Diamandakos; Jonathan Sgro; Douglas M Campbell
Journal:  Paediatr Child Health       Date:  2018-04-24       Impact factor: 2.253

7.  Neonatal and young infant sepsis by Group B Streptococci and Escherichia coli: a single-center retrospective analysis in Germany-GBS screening implementation gaps and reduction in antibiotic resistance.

Authors:  Maren Doenhardt; Barbara Seipolt; Lars Mense; Jennifer Lucia Winkler; Alexander Thürmer; Mario Rüdiger; Reinhard Berner; Jakob Armann
Journal:  Eur J Pediatr       Date:  2020-05-23       Impact factor: 3.183
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.